Pain News and Research

Latest Pain News and Research

New drug helps children and young adults who have severe pain from sickle cell disease

New drug helps children and young adults who have severe pain from sickle cell disease

Hispanic women twice as likely as white women to be affected by vulvodynia

Hispanic women twice as likely as white women to be affected by vulvodynia

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

FSMB joins with partners to educate health care professionals on safe prescribing of opioid analgesics

FSMB joins with partners to educate health care professionals on safe prescribing of opioid analgesics

Basic hospice strategies can make last days of dying inpatients more comfortable and dignified

Basic hospice strategies can make last days of dying inpatients more comfortable and dignified

ASA's recommendations to help patients avoid unnecessary tests for chronic pain

ASA's recommendations to help patients avoid unnecessary tests for chronic pain

Patients who arrive at hospital during off-hours are more likely to die

Patients who arrive at hospital during off-hours are more likely to die

Scientists identify channel that acts as 'brake', limiting spontaneous pain

Scientists identify channel that acts as 'brake', limiting spontaneous pain

Magnetoencephalography can be used to control and train specific targeted brain regions

Magnetoencephalography can be used to control and train specific targeted brain regions

Levels of depression and anxiety are higher in people with severe rheumatoid arthritis

Levels of depression and anxiety are higher in people with severe rheumatoid arthritis

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

BioLineRx gets approval to begin CE Mark registration trial of BL-5010P for skin lesion treatment

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Tips to prevent winter sport injuries

Tips to prevent winter sport injuries

Researchers find that uninsured patients are less likely to be transferred to another hospital

Researchers find that uninsured patients are less likely to be transferred to another hospital

Queen's University Belfast scientists receive international recognition for research on microneedles

Queen's University Belfast scientists receive international recognition for research on microneedles

Researchers conduct study to evaluate musculoskeletal pain outcomes after motor vehicle collision

Researchers conduct study to evaluate musculoskeletal pain outcomes after motor vehicle collision

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

University of Huddersfield scientist awarded prestigious Clulow Award by British Pain Society

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.